Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Irina Dobromilskaya"'
Autor:
Charles M. Rudin, Christine L. Hann, Irina Dobromilskaya, Sara C. Murphy, Luigi Marchionni, Eric E. Gardner, Rebekah L. Zinn
PDF file - 927K, Supplemental Figure 1 (associated with Figure 2). Expression of IGF-1R, IR, ERK, and AKT does not correlate with sensitivity to OSI-906 in SCLC cell lines. Supplemental Figure 2 (associated with Figure 4). Treatment with OSI-906 resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a78945a6740cde754a18bd231c1387
https://doi.org/10.1158/1535-7163.22500906
https://doi.org/10.1158/1535-7163.22500906
Autor:
Charles M. Rudin, Phuoc T. Tran, Yoon-Jae Cho, Khaled Aziz, Sarah N.H. Chatley, Saravanan Thiyagarajan, Rajendra P. Gajula, Sara C. Murphy, Irina Dobromilskaya, Timothy F. Burns
Supplementary Data PDF file - 114K, Supplemental Table 1 Mutational status of cell lines studied
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34f4018b3b91f80786ced750d55fcb99
https://doi.org/10.1158/1541-7786.22517365
https://doi.org/10.1158/1541-7786.22517365
Autor:
Charles M. Rudin, Christine L. Hann, Peter B. Illei, Irina Dobromilskaya, Joyce Osanyingbemi-Obidi
The Notch signaling pathway is a critical embryonic developmental regulatory pathway that has been implicated in oncogenesis. In non–small cell lung cancer (NSCLC), recent evidence suggests that Notch signaling may contribute to maintenance of a ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ee472df54f047257756c3d385d5be55
https://doi.org/10.1158/1541-7786.c.6542065
https://doi.org/10.1158/1541-7786.c.6542065
Autor:
Charles M. Rudin, Phuoc T. Tran, Yoon-Jae Cho, Khaled Aziz, Sarah N.H. Chatley, Saravanan Thiyagarajan, Rajendra P. Gajula, Sara C. Murphy, Irina Dobromilskaya, Timothy F. Burns
Supplementary Figures PDF file - 3634K, S1 TWIST1 specific shRNAs suppress TWIST1 transcript and protein levels. S2 Mouse Twist1 can rescue the anti-proliferative effects of knockdown of human TWIST1 in A549 cells. S3 Growth inhibition by silencing T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b7526f69acb9b527677e5290ef5dc1a
https://doi.org/10.1158/1541-7786.22517362.v1
https://doi.org/10.1158/1541-7786.22517362.v1
Autor:
Charles M. Rudin, Christine L. Hann, Irina Dobromilskaya, Sara C. Murphy, Luigi Marchionni, Eric E. Gardner, Rebekah L. Zinn
PDF file - 71K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aea02ec4a4e0450449d881a676f7f84
https://doi.org/10.1158/1535-7163.22500909.v1
https://doi.org/10.1158/1535-7163.22500909.v1
Autor:
Charles M. Rudin, Christine L. Hann, Irina Dobromilskaya, Sara C. Murphy, Luigi Marchionni, Eric E. Gardner, Rebekah L. Zinn
New therapies are critically needed to improve the outcome for patients with small cell lung cancer (SCLC). Insulin-like growth factor 1 receptor (IGF-1R) inhibition is a potential treatment strategy for SCLC: the IGF-1R pathway is commonly upregulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c932d9c946559966fee8434d5dce11fe
https://doi.org/10.1158/1535-7163.c.6536622.v1
https://doi.org/10.1158/1535-7163.c.6536622.v1
Autor:
Charles M. Rudin, D. Neil Watkins, Daniel L. Wilburn, Jared S. Hierman, Xue Lin, Leslie Cope, Sara C. Murphy, Irina Dobromilskaya, Elizabeth A. Sugar, Vincent C. Daniel, Christine L. Hann
Supplementary Figure 1 from Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3459dbe793affe2d2e7f8548066fb9fe
https://doi.org/10.1158/0008-5472.22371180
https://doi.org/10.1158/0008-5472.22371180
The antiangiogenic agent bevacizumab has been approved for the treatment of non–small cell lung cancer (NSCLC), although the survival benefit associated with this agent is marginal, and toxicities and cost are substantial. A recent screen for selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ba12faa65d325f6860020d522298a5d
https://doi.org/10.1158/0008-5472.c.6502943.v1
https://doi.org/10.1158/0008-5472.c.6502943.v1
Autor:
Christine L. Hann, Charles M. Rudin, Gary L. Gallia, Irina Dobromilskaya, Leslie Cope, John T. Poirier, Nick Connis, Eric E. Gardner
PDF file - 399KB, Supplemental Figure 3. SCLC PDXs and cell lines express mTOR pathway components and the combination of ABT-737 and rapamycin is well tolerated in PDX-bearing mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c819cbe9187037f259d251d54d0bbd4
https://doi.org/10.1158/0008-5472.22403946.v1
https://doi.org/10.1158/0008-5472.22403946.v1